Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Leuk Lymphoma. 2022 Dec;63(12):2912-2917. doi: 10.1080/10428194.2022.2103808. Epub 2022 Aug 7.
Improved biomarkers are needed to guide patient selection for autologous stem cell transplantation (ASCT) and post-ASCT maintenance therapies in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the prognostic value of minimal residual disease (MRD) using immunoglobulin-based high-throughput sequencing (Ig-HTS), we analyzed pre- and post-ASCT peripheral blood and pre-ASCT apheresis stem cell (ASC) samples in 36 cHL patients. A tumor clonotype was detected in only 12 patients (33%). Among these patients, MRD within plasma samples was closely associated with impending relapse. All patients (n = 3) with detectable MRD in any post-ASCT plasma sample relapsed (100% specificity), and MRD was not detected in any patients in remission. MRD testing from cellular specimens (peripheral blood mononuclear cell or ASC samples) was not associated with relapse. In this small cohort, plasma-based MRD testing appeared to be a promising biomarker in cHL, but given low clonotype detection rates with Ig-HTS, alternative MRD approaches should be investigated.
需要改进生物标志物，以指导复发/难治性经典霍奇金淋巴瘤 (cHL) 患者进行自体干细胞移植 (ASCT) 和 ASCT 后维持治疗的选择。为了使用基于免疫球蛋白的高通量测序 (Ig-HTS) 评估微小残留病 (MRD) 的预后价值，我们分析了 36 例 cHL 患者的 ASCT 前和 ASCT 后外周血和 ASCT 前的造血干细胞 (ASC) 样本。仅在 12 名患者（33%）中检测到肿瘤克隆型。在这些患者中，血浆样本中的 MRD 与即将复发密切相关。任何 ASCT 后血浆样本中可检测到 MRD 的所有患者（n=3）均复发（特异性 100%），而缓解期患者均未检测到 MRD。细胞标本（外周血单核细胞或 ASC 样本）中的 MRD 检测与复发无关。在这个小队列中，基于血浆的 MRD 检测似乎是 cHL 有前途的生物标志物，但鉴于 Ig-HTS 的克隆型检测率较低，应研究替代的 MRD 方法。
